The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high risk multiple myeloma (SWOG-1211).
 
Saad Zafar Usmani
Consulting or Advisory Role - Abbvie; Amgen; Bristol-Myers Squibb/Celgene; Celgene; Genentech; Gilead Sciences; GlaxoSmithKline; Janssen Oncology; Karyopharm Therapeutics; Merck; Oncopeptides; Seagen; Skyline Diagnostics; Takeda
Speakers' Bureau - Amgen; Bristol-Myers Squibb/Celgene; Janssen Oncology; Sanofi; Takeda
Research Funding - Amgen; Array BioPharma; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen Oncology; Merck; Pharmacyclics; Sanofi; Seagen; Skyline Diagnostics
 
Antje Hoering
Research Funding - eUSA, Hookipa (Inst)
 
Sikander Ailawadhi
Honoraria - Amgen (Inst); Amgen (Inst); AstraZeneca (Inst); BMS (Inst); Janssen (Inst)
Consulting or Advisory Role - Beigene; Celgene; GlaxoSmithKline; Oncopeptides; Sanofi; Takeda
Research Funding - Amgen (Inst); BMS (Inst); Cellectar (Inst); Janssen Biotech (Inst); MedImmune (Inst); Pharmacyclics (Inst); Phosplatin Therapeutics (Inst); Xencor (Inst)
 
Rachael Sexton
No Relationships to Disclose
 
Brea Lipe
Consulting or Advisory Role - Bristol Meyers; GlaxoSmithKline; Janssen Oncology; Karyopharm Therapeutics; Takeda
Research Funding - Amgen (Inst); Celgene (Inst); cellectar (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Seagen (Inst)
 
Jason Neil Valent
No Relationships to Disclose
 
Michael Alan Rosenzweig
No Relationships to Disclose
 
Jeffrey A. Zonder
Consulting or Advisory Role - Alnylam; Amgen; Bristol-Myers Squibb; Caelum Biosciences; Celgene; Intellia Therapeutics; Janssen; Oncotherapeutics; Prothena; Takeda
Research Funding - Bristol-Myers Squibb; Celgene
 
Madhav V. Dhodapkar
Consulting or Advisory Role - Janssen Oncology; lava therapeutics; Roche/Genentech
 
Natalie Scott Callander
Research Funding - Cellectar
 
Todd M. Zimmerman
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Peter M. Voorhees
Consulting or Advisory Role - Abbvie/Genentech; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Oncopeptides; Pfizer; Sanofi; Secura Bio
Research Funding - Abbvie (Inst); GlaxoSmithKline (Inst); Janssen (Inst); TeneoBio (Inst)
Travel, Accommodations, Expenses - Sanofi
(OPTIONAL) Uncompensated Relationships - GlaxoSmithKline
 
Brian G. Durie
Consulting or Advisory Role - Amgen; Bristol Myers Squibb Foundation; Janssen Biotech; Takeda
 
S. Vincent Rajkumar
Honoraria - Imedex; Research to Practice; Survivornet
Patents, Royalties, Other Intellectual Property - Authorship Royalties from Up To Date
 
Paul G. Richardson
Consulting or Advisory Role - Celgene; Janssen; Jazz Pharmaceuticals; Karyopharm Therapeutics; Oncopeptides; Sanofi; Secura Bio; Takeda
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Oncopeptides (Inst); Takeda (Inst)
 
Robert Z. Orlowski
Stock and Other Ownership Interests - Asymmetric Therapeutics
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Celgene; EcoR1 Capital; GlaxoSmithKline; Ionis Pharmaceuticals; Janssen; Kite, a Gilead Company; Legend Biotech; Molecular Partners; Regeneron; Sanofi; Takeda
Research Funding - BioTheryX